Nemaura has received an investment commitment of £12 million from private investors to expand its Memspatch microneedle transdermal liquid delivery technology platform. The funding is non-dilutive—it does not require Nemaura to sell any equity. “The money will allow us to develop the Memspatch for a number of injectable products and fast-track their approval to market launch”, said Dr Faz Chowdhury, CEO of Nemaura Pharma.
Conventional injection technology uses a single needle to administer the drug. A trained professional is usually required to apply the injection. For the patient, there is often pain, largely from the entry wound from the needle and its passage into the skin or muscle, but in some cases from the trauma associated with concentrating the entire dose into a small region of the body.
The Memspatch uses microneedle technology to insert several small needles no more than few millimetres into the skin. The dose is dispersed over a larger surface area than occurs with a single needle, facilitating faster absorption. The device is designed to overcome operator dependence on dosing consistency. The shorter needles mean less pain, and a reduced risk of needle-stick injury. The system is user-friendly, and can be self-administered—a particular advantage for chronic conditions and settings where healthcare professionals are scarce or difficult to access.
“There are all kinds of products currently in development that cannot be administered orally and must be administered parenterally”, explained Dr Chowdhury. “The Memspatch is intended to provide a minimally invasive means of parenteral delivery of medications, with minimal operator dependence and discomfort—our long-term objective is to make it the system of choice for a wide range of injectable products”.
Cautionary Statement Regarding Forward Looking Statements.
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Nemaura’s ongoing studies, including the safety and efficacy of Nemaura’s Memspatch system, the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell the Memspatch system, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Memspatch system.
Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.